FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904691324> ?p ?o ?g. }

• W2904691324 abstract "Epidemiological evidence has suggested a link between use of beta₂-agonists and increased asthma mortality. Much debate has surrounded possible causal links for this association, and whether regular (daily) long-acting beta₂-agonists (LABAs) are safe, particularly when used in combination with inhaled corticosteroids (ICSs). This is an update of a Cochrane Review that now includes data from two large trials including 11,679 adults and 6208 children; both were mandated by the US Food and Drug Administration (FDA). OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS.We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trials registers for unpublished trial data. We also checked FDA submissions in relation to salmeterol. The date of the most recent search was 10 October 2018.We included parallel-design randomised trials involving adults, children, or both with asthma of any severity who were randomised to treatment with regular salmeterol and ICS (in separate or combined inhalers) versus the same dose of ICS of at least 12 weeks in duration.We conducted the review according to standard procedures expected by Cochrane. We obtained unpublished data on mortality and SAEs from the sponsors, from ClinicalTrials.gov, and from FDA submissions. We assessed our confidence in the evidence according to current GRADE recommendations.We have included in this review 41 studies (27,951 participants) in adults and adolescents, along with eight studies (8453 participants) in children. We judged that the overall risk of bias was low for all-cause events, and we obtained data on SAEs from all study authors. All except 542 adults (and none of the children) were given salmeterol and fluticasone in the same (combination) inhaler.DeathsEleven of a total of 14,233 adults taking regular salmeterol and ICS died, as did 13 of 13,718 taking regular ICS at the same dose. The pooled Peto odds ratio (OR) was 0.80 (95% confidence interval (CI) 0.36 to 1.78; participants = 27,951; studies = 41; I² = 0%; moderate-certainty evidence). In other words, for every 1000 adults treated for 25 weeks, one death occurred among those on ICS alone, and the corresponding risk among those taking salmeterol and ICS was also one death (95% CI 0 to 2 deaths).No children died, and no adults or children died of asthma, so we remain uncertain about mortality in children and about asthma mortality in any age group.Non-fatal serious adverse eventsA total of 332 adults receiving regular salmeterol with ICS experienced a non-fatal SAE of any cause, compared to 282 adults receiving regular ICS. The pooled Peto OR was 1.14 (95% CI 0.97 to 1.33; participants = 27,951; studies = 41; I² = 0%; moderate-certainty evidence). For every 1000 adults treated for 25 weeks, 21 adults on ICS alone had an SAE, and the corresponding risk for those on salmeterol and ICS was 23 adults (95% CI 20 to 27).Sixty-five of 4229 children given regular salmeterol with ICS suffered an SAE of any cause, compared to 62 of 4224 children given regular ICS. The pooled Peto OR was 1.04 (95% CI 0.73 to 1.48; participants = 8453; studies = 8; I² = 0%; moderate-certainty evidence). For every 1000 children treated for 23 weeks, 15 children on ICS alone had an SAE, and the corresponding risk for those on salmeterol and ICS was 15 children (95% CI 11 to 22).Asthma-related serious adverse eventsEighty and 67 adults in each group, respectively, experienced an asthma-related non-fatal SAE. The pooled Peto OR was 1.15 (95% CI 0.83 to 1.59; participants = 27,951; studies = 41; I² = 0%; low-certainty evidence). For every 1000 adults treated for 25 weeks, five receiving ICS alone had an asthma-related SAE, and the corresponding risk among those on salmeterol and ICS was six adults (95% CI 4 to 8).Twenty-nine children taking salmeterol and ICS and 23 children taking ICS alone reported asthma-related events. The pooled Peto OR was 1.25 (95% CI 0.72 to 2.16; participants = 8453; studies = 8; I² = 0%; moderate-certainty evidence). For every 1000 children treated for 23 weeks, five receiving an ICS alone had an asthma-related SAE, and the corresponding risk among those receiving salmeterol and ICS was seven children (95% CI 4 to 12).We did not find a difference in the risk of death or serious adverse events in either adults or children. However, trial authors reported no asthma deaths among 27,951 adults or 8453 children randomised to regular salmeterol and ICS or ICS alone over an average of six months. Therefore, the risk of dying from asthma on either treatment was very low, but we remain uncertain about whether the risk of dying from asthma is altered by adding salmeterol to ICS.Inclusion of new trials has increased the precision of the estimates for non-fatal SAEs of any cause. We can now say that the worst-case estimate is that at least 152 adults and 139 children must be treated with combination salmeterol and ICS for six months for one additional person to be admitted to the hospital (compared to treatment with ICS alone). These possible risks still have to be weighed against the benefits experienced by people who take combination treatment.However more than 90% of prescribed treatment was taken in the new trials, so the effects observed may be different from those seen with salmeterol in combination with ICS in daily practice." @default.
• W2904691324 created "2018-12-22" @default.
• W2904691324 creator A5006036140 @default.
• W2904691324 creator A5065716950 @default.
• W2904691324 creator A5075061856 @default.
• W2904691324 creator A5076522546 @default.
• W2904691324 creator A5079070105 @default.
• W2904691324 date "2018-12-03" @default.
• W2904691324 modified "2023-10-09" @default.
• W2904691324 title "Inhaled steroids with and without regular salmeterol for asthma: serious adverse events" @default.
• W2904691324 cites W102833839 @default.
• W2904691324 cites W1541897129 @default.
• W2904691324 cites W1543855637 @default.
• W2904691324 cites W1555651758 @default.
• W2904691324 cites W1559467617 @default.
• W2904691324 cites W1594570351 @default.
• W2904691324 cites W1594832069 @default.
• W2904691324 cites W1600041372 @default.
• W2904691324 cites W1760629554 @default.
• W2904691324 cites W1885961906 @default.
• W2904691324 cites W1902445705 @default.
• W2904691324 cites W1906463009 @default.
• W2904691324 cites W1917912133 @default.
• W2904691324 cites W1924413082 @default.
• W2904691324 cites W1964105299 @default.
• W2904691324 cites W1968742740 @default.
• W2904691324 cites W1970636476 @default.
• W2904691324 cites W1971093510 @default.
• W2904691324 cites W1972220173 @default.
• W2904691324 cites W1974262863 @default.
• W2904691324 cites W1975914622 @default.
• W2904691324 cites W1977298101 @default.
• W2904691324 cites W1979098016 @default.
• W2904691324 cites W1979792206 @default.
• W2904691324 cites W1981406037 @default.
• W2904691324 cites W1982732664 @default.
• W2904691324 cites W1987062528 @default.
• W2904691324 cites W1987703799 @default.
• W2904691324 cites W1990951259 @default.
• W2904691324 cites W1994559472 @default.
• W2904691324 cites W1994745317 @default.
• W2904691324 cites W199806695 @default.
• W2904691324 cites W1998329899 @default.
• W2904691324 cites W1998380622 @default.
• W2904691324 cites W1999493130 @default.
• W2904691324 cites W2001057495 @default.
• W2904691324 cites W2002752649 @default.
• W2904691324 cites W2003816831 @default.
• W2904691324 cites W2004371282 @default.
• W2904691324 cites W2007434636 @default.
• W2904691324 cites W2009191674 @default.
• W2904691324 cites W2010176815 @default.
• W2904691324 cites W2010867332 @default.
• W2904691324 cites W2010966573 @default.
• W2904691324 cites W2012630107 @default.
• W2904691324 cites W2013048735 @default.
• W2904691324 cites W2014561368 @default.
• W2904691324 cites W2016057535 @default.
• W2904691324 cites W2016715361 @default.
• W2904691324 cites W2017601887 @default.
• W2904691324 cites W2020046121 @default.
• W2904691324 cites W2022008229 @default.
• W2904691324 cites W2023968105 @default.
• W2904691324 cites W2024769642 @default.
• W2904691324 cites W2027285152 @default.
• W2904691324 cites W2030078295 @default.
• W2904691324 cites W2033573518 @default.
• W2904691324 cites W2034106034 @default.
• W2904691324 cites W2038694240 @default.
• W2904691324 cites W2042690921 @default.
• W2904691324 cites W2042885153 @default.
• W2904691324 cites W2045449026 @default.
• W2904691324 cites W2046179969 @default.
• W2904691324 cites W2046789363 @default.
• W2904691324 cites W2047728537 @default.
• W2904691324 cites W2049070611 @default.
• W2904691324 cites W2051671092 @default.
• W2904691324 cites W2051906837 @default.
• W2904691324 cites W2053298480 @default.
• W2904691324 cites W2054699999 @default.
• W2904691324 cites W2058386143 @default.
• W2904691324 cites W2059731052 @default.
• W2904691324 cites W2060099663 @default.
• W2904691324 cites W2061255463 @default.
• W2904691324 cites W2062114031 @default.
• W2904691324 cites W2063045365 @default.
• W2904691324 cites W2065770911 @default.
• W2904691324 cites W2066887358 @default.
• W2904691324 cites W2069105771 @default.
• W2904691324 cites W2070646431 @default.
• W2904691324 cites W2071696733 @default.
• W2904691324 cites W2073554865 @default.
• W2904691324 cites W2075621513 @default.
• W2904691324 cites W2083269086 @default.
• W2904691324 cites W2085140273 @default.
• W2904691324 cites W2086313465 @default.
• W2904691324 cites W2087666617 @default.
• W2904691324 cites W2088520852 @default.
• W2904691324 cites W2088809081 @default.
• W2904691324 cites W2090108052 @default.

• next